Preventive strategies of ovarian hyperstimulation syndrome

Journal of Experimental and Clinical Medicine

Volumn 2, Issue 2, 2010, Pages 53-62

  Huang, Jack Yu Jen ^a   Rosenwaks, Zev ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Coasting; Cryopreservation; GnRH agonist; Ovarian hyperstimulation syndrome; Polycystic ovary

Indexed keywords

ALBUMIN; CABERGOLINE; CHORIONIC GONADOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; ESTROGEN; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; METFORMIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; TRIPTORELIN;

CLINICAL TRIAL; CRYOPRESERVATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; EVENING DOSAGE; FEMALE; FERTILIZATION IN VITRO; HUMAN; INCIDENCE; INDIVIDUALIZATION; LOW DRUG DOSE; OVARY FOLLICLE DEVELOPMENT; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREDICTION; PREGNANCY RATE; PROCESS OPTIMIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

EID: 77949880365     PISSN: 18783317     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1878-3317(10)60010-1     Document Type: Review

References (125)

1. International Committee for Monitoring Assisted Reproductive Technology, de Mouzon J, Lancaster P, Nygren KG, Sullivan E, Zegers-Hochschild F, Mansour R, Ishihara O, et al. World collaborative report on assisted reproductive technology, 2002. Hum Reprod 2009, 24:2310-2320.
2. Tan SL, Steer C, Royston P, Rizk P, Mason BA, Campbell S Conception rates and in-vitro fertilisation. Lancet 1990, 335:299.
3. Tan SL, Royston P, Campbell S, Jacobs HS, Betts J, Mason B, Edwards RG Cumulative conception and livebirth rates after in-vitro fertilisation. Lancet 1992, 339:1390-1394.
4. MacDougall MJ, Tan SL, Jacobs HS In vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992, 7:597-600.
5. MacDougall MJ, Tan SL, Balen A, Jacobs HS A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod 1993, 8:233-237.
6. Chen D, Burmeister L, Goldschlag D, Rosenwaks Z Ovarian hyperstimulation syndrome: strategies for prevention. Reprod Biomed Online 2003, 7:43-49.
7. Ou YC, Kao YL, Lai SL, Kung FT, Huang FJ, Chang SY, Chang Chien CC Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: case report. Hum Reprod 2003, 18:2375-2381.
8. Golan A, Ron-El R, Herman A, Soffer Y, Wainraub Z, Caspi E Ovarian hyperstimulation syndrome: an update review. Obstet Gynaecol Survey 1989, 44:430-440.
9. Navot D, Bergh PA, Laufer N Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992, 58:249-261.
10. Cluroe AD, Synek BJ A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology 1995, 27:344-346.
11. Akdemir R, Uyan C, Emiroglu Y Acute myocardial infarction secondary thrombosis associated with ovarial hyperstimulation syndrome. Int J Cardiol 2002, 83:187-189.
12. Kligman I, Rosenwaks Z Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil Steril 2001, 76:1185-1190.
13. Muasher SJ, Oehninger S, Simonetti S, Matta J, Ellis LM, Liu HC, Jones GS, et al. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 1988, 50:298-307.
14. Licciardi FL, Liu HC, Rosenwaks Z Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995, 64:991-994.
15. Rosenwaks Z, Davis OK, Damario MA The role of maternal age in assisted reproduction. Hum Reprod 1995, 10(Suppl 1):165-173.
16. Damario MA, Davis O, Rosenwaks Z The role of maternal age in assisted reproductive technologies. Reprod Med Rev 1999, 7:141-160.
17. Seifer DB, Lambert-Messerlian G, Hogan JW, Gárdiner AC, Blazar AS, Berk CA Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997, 67:110-114.
18. Tomas C, Nuojua-Huttunen S, Martikainen H Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization. Hum Reprod 1997, 12:220-223.
19. Navot D, Rosenwaks Z, Margalioth EJ Prognostic assessment of female fecundity. Lancet 1987, 2:645-647.
20. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989, 51:651-654.
21. Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998, 69:505-510.
22. Roberts JE, Spandorfer S, Fasouliotis SJ, Kashyap S, Rosenwaks Z Taking a basal follicle-stimulating hormone history is essential before initiating in vitro fertilization. Fertil Steril 2005, 83:37-41.
23. Wu CH, Chen YC, Wu HH, Yang JG, Chang YJ, Tsai HD Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients. J Assist Reprod Genet 2009, 26:383-389.
24. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol 2009, 7:100.
25. Ho HY, Lee RK, Lin MH, Hwu YM Estradiol level on day 9 as a predictor of risk for ovarian hyperresponse during controlled ovarian hyperstimulation. J Assist Reprod Genet 2003, 20:222-226.
26. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, Bekir J, et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 1999, 71:287-293.
27. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, Yang YS, et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008, 23:160-167.
28. Broer SL, Mol BWJ, Hendriks D, Broekmans FJM The role of anti-mullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009, 91:705-714.
29. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009, 24:867-875.
30. Fanchin R, Taieb J, Lozano DHM, Ducot B, Frydman R, Bouyer J High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005, 20:923-927.
31. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007, 22:766-771.
32. Agrawal R, Conway G, Sladkevicius P, Tan SL, Engmann L, Payne N, Bekir J, et al. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 1998, 70:651-658.
33. Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, Soong YK Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endo-thelial growth factor. J Clin Endocrinol Metab 2002, 87:3300-3308.
34. Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertil Steril 1999, 72:286-292.
35. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000, 15:1037-1042.
36. Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome. Hum Reprod 2000, 15:66-71.
37. Chang FW, Chan CC, Yin CS, Wu GJ Predicted value of renin activity in a woman who had severe ovarian hyperstimulation syndrome with internal jugular vein thrombosis. Fertil Steril 2004, 82:937-939.
38. Moos J, Rezabek K, Filova V, Moosova M, Pavelkova J, Peknicova J Comparison of follicular fluid and serum levels of Inhibin A and Inhibin B with calculated indices used as predictive markers of ovarian hyperstimulation syndrome in IVF patients. Reprod Biol Endocrinol 2009, 7:86.
39. Engmann L, Maconochie N, Sladkevicius P, Bekir J, Campbell S, Tan SL The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology. Hum Reprod 1999, 14:167-171.
40. Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999, 71:808-814.
41. Whelan JG, Vlahos NF The ovarian hyperstimulation syndrome. Fertil Steril 2000, 73:883-896.
42. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 1997, 12:2359-2365.
43. Sauer MV, Paulson RJ, Lobo RA Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors. Int J Gynecol Obstet 1996, 52:259-262.
44. Maxwell KN, Cholst IN, Rosenwaks Z The incidence of both serious and minor complications in young women undergoing oocyte donation. Fertil Steril 2008, 90:2165-2171.
45. Devroey P, Aboulghar M, Garcia-Velasco J, Griesinger G, Humaidan P, Kolibianakis E, Ledger W, et al. Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod 2009, 24:764-774.
46. de Jong D, Macklon NS, Mannaerts BM, Coelingh Bennink HJ, Fauser BC High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. Hum Reprod 1998, 13:573-575.
47. Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmüller-Winzen H, Schüler A, Engel W, et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 2000, 264:29-32.
48. Ludwig M, Katalinic A, Diedrich K Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 2001, 265:175-182.
49. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005, 20:2887-2892.
50. Abdallah R, Kligman I, Davis O, Rosenwaks Z. Coasting-withholding gonadotropins until HCG administration. Sem Reprod Med In press.
51. Benadiva CA, Davis O, Kligman I, Moomjy M, Liu HC, Rosenwaks Z Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 1997, 67:724-727.
52. Forman RG, Frydman R, Egan D, Ross C, Barlow DH Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril 1990, 53:502-509.
53. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002, 17:310-313.
54. Gera PS, Tatpati LL, Allemand MC, Wentworth MA, Coddington CC Ovarian hyperstimulation syndrome: steps to maximize success and minimize effect for assisted reproductive outcome. Fertil Steril 2009 Apr 6, [Epub ahead of print].
55. Ulug U, Ben-Shlomo I, Bahceci M Predictors of success during the coasting period in high-responder patients undergoing controlled ovarian stimulation for assisted conception. Fertil Steril 2004, 82:338-342.
56. Mansour R, Aboulghar M, Serour G, Amin Y, Abou-Setta AM Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005, 20:3167-3172.
57. Ho Yuen B, Nguyen TAT, Cheung AP, Leung PCK Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting. Fertil Steril 2009, 92:499-507.
58. Delvigne A, Rozenberg S A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update 2002, 8:291-296.
59. Egbase PE, Al Sharhan M, Grudzinskas JG Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod 1999, 14:1421-1425.
60. D'Angelo A, Amso N " Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002, 3. CD002811.
61. Felberbaum RE, Reissmann T, Küpker W, Bauer O, al Hasani S, Diedrich C, Diedrich K Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol 1995, 61:151-155.
62. Itskovitz-Eldor J, Kol S, Mannaerts B Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 2000, 15:1965-1968.
63. European Recombinant LH Study Group Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001, 86:2607-2618.
64. Kol S Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004, 81:1-5.
65. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren HG Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002, 87:709-715.
66. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, Pellicer A, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online 2009, 19:486-492.
67. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008, 89:84-91.
68. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006, 12:159-168.
69. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005, 20:1213-1220.
70. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003, 88:4186-4192.
71. Humaidan P Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009, 18:630-634.
72. Humaidan P, Bredkjær HE, Westergaard LG, Yding Andersen C 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2009 Feb 5, [Epub ahead of print].
73. Dahl Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994, 9:792-799.
74. Queenan JT, Veeck LL, Toner JP, Oehninger S, Muasher SJ Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum Reprod 1997, 12:1573-1576.
75. Tummon IS, Contag SA, Thornhill AR, Session DR, Dumesic DA, Damario MA Cumulative first live birth after elective cryopre-servation of all embryos due to ovarian hyperresponsiveness. Fertil Steril 2004, 81:309-314.
76. Huddleston HG, Racowsky C, Jackson KV, Fox JH, Ginsburg ES Coasting vs. cryopreservation of all embryos for prevention of ovarian hyperstimulation syndrome in in vitro fertilization. Fertil Steril 2008, 90:1259-1262.
77. Manzanares MA, Gómez-Palomares JL, Ricciarelli E, Hernández ER Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril 2009 Feb 5, [Epub ahead of print].
78. Shaker AG, Zosmer A, Dean N, Bekir JS, Jacobs HS, Tan SL Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertil Steril 1996, 65:992-996.
79. Ferraretti AP, Gianaroli L, Magli C, Fortini D, Selman HA, Feliciani E Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 1999, 14:1457-1460.
80. D'Angelo A, Amso N Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2007, 18. CD002806.
81. Buckett W, Chian RC, Tan SL Can we eliminate severe ovarian hyperstimulation syndrome? Not completely. Hum Reprod 2005, 20:2367. author reply 2367-8.
82. Chian RC, Buckett WM, Abdul Jalil AK, Son WY, Sylvestre C, Rao D, Tan SL Natural-cycle in vitro fertilization combined with in vitro maturation of immature oocytes is a potential approach in infertility treatment. Fertil Steril 2004, 82:1675-1678.
83. Elizur SE, Chian RC, Pineau CA, Son WY, Holzer HE, Huang JY, Gidoni Y, et al. Fertility preservation treatment for young women with autoimmune disease facing treatment with gonadotoxic agents. Rheumatology (Oxford) 2008, 47:1506-1509.
84. Child TJ, Phillipsm SJ, Abdul-Jalil AK, Gulekli B, Tan SL A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 2002, 100:665-670.
85. Lim K, Lee W, Lim J IVM after interruption of COH for the prevention of OHSS. Fertil Steril 2005, 84:S84-S85.
86. Centers for Disease Control and Prevention. 2006 Assisted Reproductive Technology (ART) Report: Section 2-ART Cycles Using Fresh, Nondonor Eggs or Embryos. Atlanta: Centers for Disease Control and Prevention.
87. Andersen AN, Gianaroli L, Felberbaum R, de Mouzon J, Nygren KG Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE. Hum Reprod 2006, 21:1680-1697.
88. Gunby J, Daya S Assisted reproductive technologies (ART) in Canada: 2003 results from the Canadian ART Register. Fertil Steril 2007, 88:550-559.
89. Cha KY, Chung HM, Lee DR, Kwon H, Chung MK, Park LS, Choi DH, et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil Steril 2005, 83:1461-1465.
90. Soderstrom-Anttila V, Salokorpi T, Pihlaja M, Serenius-Sirve S, Suikkari AM Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum Reprod 2006, 21:1508-1513.
91. Buckett WM, Chian RC, Holzer H, Dean N, Usher R, Tan SL Obstetric outcomes and congenital abnormalities after in vitro maturation, in vitro fertilization, and intracytoplasmic sperm injection. Obstet Gynecol 2007, 110:885-891.
92. Edwards RG Foreword. In-vitro Maturation of Human Oocytes: Basic Science to Clinical Application 2006, xv-xx. Informa, London. S.L. Tan, R.C. Chian, W.M. Buckett (Eds.).
93. Jurema MW, Nogueira D In vitro maturation of human oocytes for assisted reproduction. Fertil Steril 2006, 86:1277-1291.
94. Chian RC, Buckett WM, Tan SL In-vitro maturation of human oocytes. Reprod Biomed Online 2004, 8:148-166.
95. Le Du A, Kadoch IJ, Bourcigaux N, Doumerc S, Bourrier MC, Chevalier N, Fanchin R, et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. Hum Reprod 2005, 20:420-424.
96. Asch RH, Ivery G, Goldsman M, Frederick JL, Stone SC, Balmaceda JP The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 1993, 8:1015-1020.
97. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohi J, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angio-genesis in a rat ovarian hyperstimulation model. Endocrinology 2006, 147:5400-5411.
98. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, Simón C, et al. Dopamine agonist caber-goline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007, 92:2931-2937.
99. Rollene NL, Amols MH, Hudson SBA, Coddington CC Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 2009, 92:1169. e15-7.
100. Gustofson RL, Segars JH, Larsen FW Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod 2006, 21:2830-2837.
101. Aboulghar MA, Mansour RT, Amin YM, Al-Inany HG, Aboulghar MM, Serour GI A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online 2007, 15:271-279.
102. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007, 15:408-412.
103. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Iliadis GS, Kolibianakis EM Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online 2009, 18:15-20.
104. Shoham Z, Weissman A, Barash A, Borenstein R, Schachter M, Insler V Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril 1994, 62:137-142.
105. Chen CD, Wu MY, Yang JH, Chen SU, Ho HN, Yang YS Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Fertil Steril 1997, 68:287-291.
106. Ben-Chetrit A, Eldar-Geva T, Gal M, Huerta M, Mimon T, Algur N, Diamant YZ, et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 2001, 16:1880-1884.
107. Chen CD, Chao KH, Yang JH, Chen SU, Ho HN, Yang YS Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril 2003, 80:86-90.
108. Shalev E, Giladi Y, Matilsky M, Ben-Ami M Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study. Hum Reprod 1995, 10:1373-1386.
109. Isik AZ, Gokmen O, Zeyneloglu HB, Kara S, Keles G, Gulekli B Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study. Eur J Obstet Gynecol Reprod Biol 1996, 70:179-183.
110. Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol 2001, 96:187-192.
111. Aboulghar M, Evers JH, Al-Inany H Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002, 2. CD001302.
112. Bellver J, Muñoz EA, Ballesteros A, Soares SR, Bosch E, Simón C, Pellicer A, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 2003, 18:2283-2288.
113. Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study. Fertil Steril 2007, 88:982-985.
114. Dunaif A, Segal KR, Futterweit W, Dobrjansky A Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165-1174.
115. Attia GR, Rainey WE, Carr BR Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001, 76:517-524.
116. Barbieri RL Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol 2000, 183:1412-1418.
117. Moll E, van der Veen F, van Wely M The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007, 13:527-537.
118. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009, 15. CD006105.
119. Visnová H, Ventruba P, Crha I, Záková J Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome. Ceska Gynekol 2003, 68:155-162.
120. Kjotrod SB, von During V, Carlsen SM Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod 2004, 19:1315-1322.
121. Önalan G, Pabuçcu R, Goktolga U, Ceyhan T, Bagis T, CincIk M Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertil Steril 2005, 84:798-801.
122. Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of met-formin for women with PCOS undergoing IVF treatment. Hum Reprod 2006, 21:1416-1425.
123. Doldi N, Persico P, Di Sebastiano F, Marsiglio E, Ferrari A Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecol Endocrinol 2006, 22:235-238.
124. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro S Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008, 17:751-755.
125. Bonilla-Musoles FM, Raga F, Castillo JC, Sanz M, Dolz M, Osborne N High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. Clin Exp Obstet Gynecol 2009, 36:78-81.